Phase III IMpassion031 study suggests atezolizumab in combination with chemotherapy shows promise in early triple-negative breast cancer

Study comparing atezolizumab plus chemotherapy to placebo plus chemotherapy, met its primary endpoint by demonstrating a statistically significant improvement in pathological complete response regardless of PD-L1 expression. Data will be discussed with regulatory authorities.